Oophorectomy, estrogen, and dementia: A 2014 update

Walter A Rocca, Brandon R. Grossardt, Lynne T. Shuster

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Current evidence suggests that estrogen may have beneficial, neutral, or detrimental effects on the brain depending on age, type of menopause (natural versus induced), or stage of menopause (early versus late), consistent with the timing hypothesis. Three studies have now compared women who underwent bilateral oophorectomy before menopause with referent women and consistently showed an increased risk of cognitive decline and dementia. These studies suggest a sizeable neuroprotective effect of estrogen naturally produced by the ovaries before age 50. years. In this article, we focus on neuroprotection as related to cognitive decline and dementia. Several case-control studies and cohort studies also showed neuroprotective effects in women who received estrogen treatment (ET) in the early postmenopausal stage (most commonly at ages 50-60. years). The majority of women in those observational studies had undergone natural menopause and were treated for the relief of menopausal symptoms. However, the clinical trials by the Women's Health Initiative showed that women who initiated ET alone or in combination with a progestin in the late postmenopausal stage (ages 65-79. years) experienced an increased risk of dementia and cognitive decline regardless of the type of menopause. Three observational studies have now formally tested the timing hypothesis, and showed that the neuroprotective or harmful effects of estrogen depend on age at the time of initiation of treatment and on stage of menopause. Therefore, women who undergo bilateral oophorectomy before the onset of menopause or women who experience premature or early natural menopause should be considered for hormonal treatment until the average age of natural menopause (around age 50. years). Recommendations for the use of ET by women who experience natural menopause at typical ages remain less certain, and more research is needed.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalMolecular and Cellular Endocrinology
Volume389
Issue number1-2
DOIs
StatePublished - May 25 2014

Fingerprint

Ovariectomy
Menopause
Dementia
Estrogens
Neuroprotective Agents
Observational Studies
Progestins
Brain
Therapeutics
Women's Health
Case-Control Studies
Ovary
Cohort Studies
Clinical Trials

Keywords

  • Cognitive impairment
  • Dementia
  • Estrogen
  • Menopause
  • Oophorectomy
  • Timing hypothesis

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Medicine(all)

Cite this

Oophorectomy, estrogen, and dementia : A 2014 update. / Rocca, Walter A; Grossardt, Brandon R.; Shuster, Lynne T.

In: Molecular and Cellular Endocrinology, Vol. 389, No. 1-2, 25.05.2014, p. 7-12.

Research output: Contribution to journalArticle

Rocca, Walter A ; Grossardt, Brandon R. ; Shuster, Lynne T. / Oophorectomy, estrogen, and dementia : A 2014 update. In: Molecular and Cellular Endocrinology. 2014 ; Vol. 389, No. 1-2. pp. 7-12.
@article{5670928a319b4c548b39b3002372b975,
title = "Oophorectomy, estrogen, and dementia: A 2014 update",
abstract = "Current evidence suggests that estrogen may have beneficial, neutral, or detrimental effects on the brain depending on age, type of menopause (natural versus induced), or stage of menopause (early versus late), consistent with the timing hypothesis. Three studies have now compared women who underwent bilateral oophorectomy before menopause with referent women and consistently showed an increased risk of cognitive decline and dementia. These studies suggest a sizeable neuroprotective effect of estrogen naturally produced by the ovaries before age 50. years. In this article, we focus on neuroprotection as related to cognitive decline and dementia. Several case-control studies and cohort studies also showed neuroprotective effects in women who received estrogen treatment (ET) in the early postmenopausal stage (most commonly at ages 50-60. years). The majority of women in those observational studies had undergone natural menopause and were treated for the relief of menopausal symptoms. However, the clinical trials by the Women's Health Initiative showed that women who initiated ET alone or in combination with a progestin in the late postmenopausal stage (ages 65-79. years) experienced an increased risk of dementia and cognitive decline regardless of the type of menopause. Three observational studies have now formally tested the timing hypothesis, and showed that the neuroprotective or harmful effects of estrogen depend on age at the time of initiation of treatment and on stage of menopause. Therefore, women who undergo bilateral oophorectomy before the onset of menopause or women who experience premature or early natural menopause should be considered for hormonal treatment until the average age of natural menopause (around age 50. years). Recommendations for the use of ET by women who experience natural menopause at typical ages remain less certain, and more research is needed.",
keywords = "Cognitive impairment, Dementia, Estrogen, Menopause, Oophorectomy, Timing hypothesis",
author = "Rocca, {Walter A} and Grossardt, {Brandon R.} and Shuster, {Lynne T.}",
year = "2014",
month = "5",
day = "25",
doi = "10.1016/j.mce.2014.01.020",
language = "English (US)",
volume = "389",
pages = "7--12",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Oophorectomy, estrogen, and dementia

T2 - A 2014 update

AU - Rocca, Walter A

AU - Grossardt, Brandon R.

AU - Shuster, Lynne T.

PY - 2014/5/25

Y1 - 2014/5/25

N2 - Current evidence suggests that estrogen may have beneficial, neutral, or detrimental effects on the brain depending on age, type of menopause (natural versus induced), or stage of menopause (early versus late), consistent with the timing hypothesis. Three studies have now compared women who underwent bilateral oophorectomy before menopause with referent women and consistently showed an increased risk of cognitive decline and dementia. These studies suggest a sizeable neuroprotective effect of estrogen naturally produced by the ovaries before age 50. years. In this article, we focus on neuroprotection as related to cognitive decline and dementia. Several case-control studies and cohort studies also showed neuroprotective effects in women who received estrogen treatment (ET) in the early postmenopausal stage (most commonly at ages 50-60. years). The majority of women in those observational studies had undergone natural menopause and were treated for the relief of menopausal symptoms. However, the clinical trials by the Women's Health Initiative showed that women who initiated ET alone or in combination with a progestin in the late postmenopausal stage (ages 65-79. years) experienced an increased risk of dementia and cognitive decline regardless of the type of menopause. Three observational studies have now formally tested the timing hypothesis, and showed that the neuroprotective or harmful effects of estrogen depend on age at the time of initiation of treatment and on stage of menopause. Therefore, women who undergo bilateral oophorectomy before the onset of menopause or women who experience premature or early natural menopause should be considered for hormonal treatment until the average age of natural menopause (around age 50. years). Recommendations for the use of ET by women who experience natural menopause at typical ages remain less certain, and more research is needed.

AB - Current evidence suggests that estrogen may have beneficial, neutral, or detrimental effects on the brain depending on age, type of menopause (natural versus induced), or stage of menopause (early versus late), consistent with the timing hypothesis. Three studies have now compared women who underwent bilateral oophorectomy before menopause with referent women and consistently showed an increased risk of cognitive decline and dementia. These studies suggest a sizeable neuroprotective effect of estrogen naturally produced by the ovaries before age 50. years. In this article, we focus on neuroprotection as related to cognitive decline and dementia. Several case-control studies and cohort studies also showed neuroprotective effects in women who received estrogen treatment (ET) in the early postmenopausal stage (most commonly at ages 50-60. years). The majority of women in those observational studies had undergone natural menopause and were treated for the relief of menopausal symptoms. However, the clinical trials by the Women's Health Initiative showed that women who initiated ET alone or in combination with a progestin in the late postmenopausal stage (ages 65-79. years) experienced an increased risk of dementia and cognitive decline regardless of the type of menopause. Three observational studies have now formally tested the timing hypothesis, and showed that the neuroprotective or harmful effects of estrogen depend on age at the time of initiation of treatment and on stage of menopause. Therefore, women who undergo bilateral oophorectomy before the onset of menopause or women who experience premature or early natural menopause should be considered for hormonal treatment until the average age of natural menopause (around age 50. years). Recommendations for the use of ET by women who experience natural menopause at typical ages remain less certain, and more research is needed.

KW - Cognitive impairment

KW - Dementia

KW - Estrogen

KW - Menopause

KW - Oophorectomy

KW - Timing hypothesis

UR - http://www.scopus.com/inward/record.url?scp=84901483236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901483236&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2014.01.020

DO - 10.1016/j.mce.2014.01.020

M3 - Article

C2 - 24508665

AN - SCOPUS:84901483236

VL - 389

SP - 7

EP - 12

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -